<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="210">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on March 04, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04547673</url>
  </required_header>
  <id_info>
    <org_study_id>ZSYY2020</org_study_id>
    <nct_id>NCT04547673</nct_id>
  </id_info>
  <brief_title>To Develop and Validate a Nasoendoscopic Intelligent Diagnostic System for Nasopharyngeal Carcinoma</brief_title>
  <official_title>To Develop and Validate a Nasoendoscopic Intelligent Diagnostic System for Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nasopharyngeal carcinoma (NPC) occurs at a high frequency in southern China, northern Africa,&#xD;
      and Alaska, with a reported incidence of 30 cases per 100 000 in Guangdong Province.&#xD;
      Endoscopic examination and biopsy are the main methods used for detection and diagnosis of&#xD;
      NPC. Early NPC patients achieve favourable prognoses after concurrent radiotherapy and&#xD;
      chemotherapy in compassion with advanced NPC patients.&#xD;
&#xD;
      Here, the investigators focused on the utility of artificial intelligence to detect early&#xD;
      NPC, which based on white light imaging (WLI) and Narrow-band imaging (NBI) nasoendoscopic&#xD;
      examination. Having access to this unique population provides an unprecedented opportunity to&#xD;
      investigate the effect of intelligent system on diverse nasopharyngeal lesions detection and&#xD;
      develop a novel Computer-Aided Diagnosis System.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological diagnosis</measure>
    <time_frame>baseline</time_frame>
    <description>All lesions, detected by either WLI or NBI, are biopsied. 2 experienced pathologists, who were blinded to the endoscopic and intelligent assessment, evaluate the pathological nature of the biopsied lesion independently, and 2 professors with over 10 years of experience in Otolaryngology and pathology department are consulted in cases of disagreement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lesion range</measure>
    <time_frame>baseline</time_frame>
    <description>All images in which lesions are pathologically diagnosed as NPC are collected. 2 experienced pathologists, who were blinded to the endoscopic and intelligent assessment, delineated the malignant area in the images independently, and 2 professors with over 10 years of experience in Otolaryngology department are consulted in cases of disagreement.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Otolaryngological Disease</condition>
  <condition>Artificial Intelligence</condition>
  <arm_group>
    <arm_group_label>NPC group</arm_group_label>
    <description>Patients pathologically diagnosed as NPC by agreement of 2 experienced pathologists who were blinded to the corresponding endoscopic assessment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-NPC group</arm_group_label>
    <description>Patients pathologically diagnosed as non-NPC (including inflammatory hyperplasia, Atypical hyperplasia, Papilloma etc.) by agreement of 2 experienced pathologists who were blinded to the corresponding endoscopic assessment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>rigid nasal endoscopes</intervention_name>
    <description>The endoscope is introduced through the nasal passage to observe, in sequence, the posterior nostril, superior and posterior walls of the nasopharynx, torus tubarius, pharyngeal opening of the auditory tube, and RosenmuÂ¨ller recess. The imaging light mode is set to conventional WLI and subsequently switch to NBI during the procedure, and representative images are collected and preserve for further analysis. All lesions, detected by either WLI or NBI, are biopsied.</description>
    <arm_group_label>NPC group</arm_group_label>
    <arm_group_label>Non-NPC group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients at the outpatient department of otolaryngology at the First Affiliated Hospital of&#xD;
        Sun Yat-sen University, Guangzhou, People's Republic of China, or patients at Sun Yat-Sen&#xD;
        University Cancer Center, with risk factors including any of the following: Cantonese&#xD;
        ethnicity, NPC family history, Epstein-Barr virus detection, any symptom of nasal&#xD;
        obstruction, sense of peculiar smell, blood-stained nasal discharge, epistaxis, ear&#xD;
        fullness, tinnitus, hearing loss, diplopia, headache, or cervical mass.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Older than 18 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refuse to sign the informed consent statement&#xD;
&#xD;
          -  Patients who have contraindications, e.g. coagulation dysfunction, drug allergy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Weiping Wen, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Otolaryngology Department, First Affiliated Hospital of Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yihui Wen, Ph.D</last_name>
    <phone>+86-13480200660</phone>
    <email>wenyihui@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yudong Long, M.D.</last_name>
    <phone>+86-18312225326</phone>
    <email>Longyd@mail2.sysu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>501180</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yihui Wen, Ph.D</last_name>
      <phone>8613480200660</phone>
      <email>wenyihui@mail.sysu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yudong Long, M.D.</last_name>
      <phone>86 18312225326</phone>
      <email>Longyd@mail2.sysu.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Yudong Long, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Sun, Ph.D</last_name>
      <email>sunying@sysucc.org.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Zhang, Doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2022</verification_date>
  <study_first_submitted>September 4, 2020</study_first_submitted>
  <study_first_submitted_qc>September 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>January 26, 2022</last_update_submitted>
  <last_update_submitted_qc>January 26, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Weiping Wen</investigator_full_name>
    <investigator_title>Vice President of First Affiliated Hospital, Sun Yat-Sen University; President of sixth Affiliated Hospital, Sun Yat-Sen University</investigator_title>
  </responsible_party>
  <keyword>Nasopharyngeal Carcinoma</keyword>
  <keyword>Endoscopy</keyword>
  <keyword>Narrow-Band Imaging</keyword>
  <keyword>White-Light Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Otorhinolaryngologic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

